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Point-of-care testingObjective: To develop and evaluate a paper-based point-of-care HPV serology test to determine if an
individual has received two or more HPV immunizations.
Methods: The paper-based immunoassay was constructed using a nitrocellulose lateral flow strip with
adsorbed HPV16 virus-like particles serving as the capturing moiety. Three capture zones containing
virus-like particles were placed in series to allow for visual discrimination between high and low
HPV16 plasma antibody concentrations. A plasma separation membrane was used to allow whole blood
to be applied directly to the assay. All reagents were dried on glass fiber pads during device fabrication
and were rehydrated with buffer at the time of use. A pilot study consisting of 35 subjects with a history
of zero, one, two or three HPV vaccines was conducted to evaluate the immunoassay. The completed
paper-based immunoassays were scanned for visual interpretation by three researchers who were
blinded to the true results and separately evaluated quantitatively using MATLAB.
Results: For the 28 tests valid for analysis, fifteen subjects reported receiving two or more HPV vaccines,
three reported receiving one, and ten reported having no HPV vaccinations. The paper-based immunoas-
says for all fifteen subjects who reported having received two or more HPV vaccines were judged positive
by all researchers. Twelve of the thirteen tests from individuals reporting one or zero vaccinations were
deemed negative by all observers. One test from an unvaccinated individual was judged positive by two
out of three reviewers. Quantitatively, all tests were correctly separated between the two groups.
Conclusions: We successfully designed and tested a HPV serology test amenable to the point-of-care. The
device showed promising results in a pilot study for discriminating between those who received two or
more HPV vaccinations and those who did not. Furthermore, this device offers a platform for producing
other semi-quantitative point-of-care serological tests.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
More than 520,000 new cases of cervical cancer and 265,000
related deaths occur annually worldwide [1]. Over 85% of cases
of and deaths due to cervical cancer occur in low- and middle-
income countries (LMICs), where cervical cancer is the third
leading cause of cancer death among women [1]. LMICs bear a
disproportional burden of cervical cancer primary due to the diffi-
culty of implementing prevention and screening programs in theselocations [2]. Infection with the human papillomavirus (HPV) is the
cause of virtually all cases of cervical cancer [3]; globally, HPV16
and HPV18 types are responsible for approximately 70% of cervical
cancers [4]. Vaccines to prevent HPV infection have the potential to
drastically reduce the global burden of cervical cancer [5]. Three U.
S. Food and Drug-Administration approved HPV vaccines, Cervarix,
Gardasil, and Gardasil-9, are commercially available to protect
against HPV16 and HPV18 [5–7]. Gardasil also protects against
HPV6 and HPV11 which cause 90% of genital warts [8]. Random-
ized, prospective studies have demonstrated the efficacy of
Cervarix and Gardasil to prevent HPV16 and HPV18 infections,
and HPV16- or HPV18-related cervical intraepithelial neoplasia
(CIN) [5,8,9]. More recently a nonavalent vaccine, Gardasil-9, was
developed that provides protection against five additional
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mately 15–20% of cervical cancers[10]. Thus, immunization with
Gardasil-9 may potentially prevent 90% of cervical cancers [10].
Wide-scale adoption of HPV vaccines is predicted to signifi-
cantly lower the incidence of cervical cancer worldwide, and
reduce global disparities in cervical cancer incidence [7]. The cost
of the three-dose HPV series in the United States is approximately
$390 for the Cervarix Vaccine, $480 for Gardasil and $530 for
Gardasil-9 [11]. However, the prices of the vaccines vary signifi-
cantly by region, from as little as $5 to as much as $187 per dose
[12]. Recent studies suggest that two doses of vaccine may provide
protective immunity [13,14] and be more cost-effective than the
three-dose series [15]. However, cost remains the biggest barrier
to national implementation of the HPV vaccine in LMICs [16]. For
countries that are eligible for financial assistance through the
Global Alliance for Vaccines and Immunizations (GAVI), this barrier
is greatly reduced. However, currently countries are only eligible
for GAVI support if the three-year average of their gross national
income is at or below $1580 per capita [17]. Thus, many LMICs
are not eligible for GAVI support, and cost continues to be a major
barrier to access. Furthermore, GAVI support is temporary and
seeks to transition member countries toward government-funded
vaccination programs.
Lack of comprehensive medical records in LMICs [18] presents
another challenge to national HPV immunization programs. Absent
medical records, providers must rely on patient self-reporting to
assess whether a patient has received all recommended doses of
vaccine. This can lead to re-vaccination of individualswho have pre-
viously received sufficient doses of the vaccine. In order to optimize
cost-effectiveness, it is critical that vaccines are provided only to
those who have not received the full series of the vaccine. The accu-
racy of self-reported vaccine history varies depending on the vac-
cine [19]. A study evaluating the accuracy of self-reported HPV
vaccination history among adolescents in urban US cities revealed
major inaccuracies [20]. Only 54% (36/66) of thosewhohad received
at least one dose of the vaccine correctly reported having had the
vaccine, and only 35% (17/48) of those who had received all three
vaccines correctly self-reported having all three doses [20]. Due to
the under-reporting of HPV vaccine status and the lack of reliable
medical records in many developing countries, there is a significant
possibility of unnecessary re-vaccination, which wastes critical
resources in both GAVI-eligible and GAVI-ineligible countries.
HPV immunization status can be determined by measuring the
serum concentration of HPV antibodies. Currently, serum HPV
antibody concentration can only be measured using a virus like
particle (VLP) enzyme-linked immunosorbent assay (ELISA) or a
neutralization assay [21,22]. However, both of these assays tradi-
tionally require sophisticated laboratory equipment and highly
trained personnel. Low-cost, point-of-care alternatives to these
tests are needed to help assess whether patients have previously
received two or more doses of HPV vaccine in order to facilitate
efficient vaccination programs. Recently, Fu et al. reported
instrument-free two-dimensional paper networks (2DPNs) to per-
form multistep immunoassays at the point-of-care [23]. In this
paper, we build on this approach to develop an equipment-free
rapid paper immunoassay to detect antibodies to HPV16 from a
finger prick sample of capillary blood to determine HPV immuniza-
tion status at the point-of-care. We report results from a pilot
study of 28 subjects to evaluate the whether an individual has
received two or more doses of the Gardasil or Cervarix vaccines.2. Methods
Fig. 1(A) shows a photograph of the two-dimensional lateral
flow assay to detect HPV antibodies from a drop of capillary blood.An important design consideration is to discriminate between vac-
cinated individuals and individuals with a history of HPV infection.
Some individuals with a history of HPV infection develop detect-
able levels of antibodies to HPV; however, these levels are lower
than levels seen in vaccinated individuals. The assay is designed
to detect HPV16 antibodies. We chose HPV16 because a study
using a competitive Luminex immunoassay (cLIA) demonstrated
significantly higher HPV16 antibody geometric mean titers in vac-
cinated individuals relative to those with a history of natural
HPV16 infection [24]. Using the cLIA method, Villa et al. demon-
strated that this difference is much greater for HPV16 than for
HPV18 [24] resulting in a better assay signal-to-noise ratio.
Because all approved HPV vaccines contain both HPV16 and
HPV18 VLPs, an individual vaccinated against HPV18 would also
be vaccinated against HPV16, and vice versa. Measuring HPV16
serostatus infers protection against HPV18. The assay consists of
a lateral flow strip with three capture zones to capture HPV16 anti-
bodies from the plasma sample and a positive control zone. HPV16
L1 virus like particles (VLPs) are immobilized at the three capture
zones and human immunoglobulin (IgG) is immobilized at the pos-
itive control zone. Three test zones were included to aid in discrim-
ination between vaccinated individuals and those with a history of
natural HPV infection. This provides serial dilution on the test
itself, allowing for discrimination between high and low levels of
anti-HPV antibodies. Preliminary tests were performed with
pooled serum from individuals with a history of HPV16 infection
(provided by the National Institute of Biological Safety and Con-
trols, Hertfordshire, England) and plasma from an individual docu-
mented to have received three doses of the Gardasil vaccine. These
tests revealed that a single test zone did not allow for visual dis-
crimination of results when the test was performed using serum
from an individual with a natural HPV16 infection and one who
had received three doses of the HPV vaccine. However, by using
three test zones test results for these two samples were visually
apparent (data not shown).
As shown in Fig. 1(A), the device consists of a nitrocellulose
membrane with HPV16 VLPs immobilized at three test zones and
human IgG immobilized at the positive control zone, a cellulose
wicking pad, a plasma separation membrane (right side) and three
glass fiber pads, one of which contains dried detection antibody
(left side), all adhered to a thin acetate sheet. On the right side of
the device, the plasma separation membrane is connected via a
nitrocellulose leg to the main lateral flow strip. On the left side
of the device, three glass fiber pads are placed on exposed adhe-
sive. The middle pad contains dried anti-human IgG conjugated
to colloidal gold. The device is operated by placing a blood sample
on the plasma separation membrane and rehydrating the three
glass fiber pads with phosphate buffered saline with 0.05% Tween
20(PBST). The plasma separation membrane allows the plasma to
pass on to the nitrocellulose strip but retains red blood cells. The
adhesive cover is removed from the left side of the device. Once
the plasma reaches the plasma separation line, shown in Fig. 1
(A), the device is folded in half along the midline. This places the
glass fiber pads in direct contact with the main lateral flow strip
and initiates sequential flow of the first wash buffer, labeled detec-
tion antibody, and final wash buffer.2.1. Production of HPV16 L1 virus-like particles
HPV16 L1 virus-like-particles were produced by transfecting
293TT cells with a plasmid expressing a codon-modified HPV16L1
(p16L1h) gene [25]. The plasmid was supplied from Dr. Susanna
Pang from the National Cancer Institute Laboratory of Cellular
Oncology. The methods to produce human papillomavirus pseu-
doviruses have been published in detail previously [26–29].
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Fig. 1. Two-dimensional paper network to detect human antibodies against HPV 16. (A) Device overview. The device consists of a nitrocellulose membrane with HPV16 virus-
like particles immobilized at various concentrations at three test zones (1, 2, and 3), a cellulose wicking pad on the right and a plasma separation membrane, and three glass
fiber pads, one of which contains dried detection antibody, on the left. All are adhered to a thin acetate sheet. The dotted line indicates where the device is folded to start the
flow of reagents through capillary action. (B) All supplies needed to perform the assay at the point-of care. The supplies consist of the two-dimensional paper network device,
15 mL of phosphate-buffered saline with 0.05% Tween-20, an alcohol prep pad, a Band-Aid, a high-flow lancet, a 20 lL microsafe capillary tube and a 20 lL and 40 lL exact
volume transfer pipette.
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(National Cancer Institute Laboratory of Cellular Oncology) were
plated on a 225 cm2 flask in 50 mL of Dulbecco’s Modified Eagle
Medium (DMEM) with 10% fetal bovine serum, 1% non-essential
amino acids and 1% Glutamax-I (Thermo Fisher Scientific). Imme-
diately prior to transfection, 112.5 lg p16l1 h DNA was added to
5.6 mL Opti-MEM (Thermo Fisher Scientific) and in a separate tube
247.5 lL of Lipofectamine 2000 (Thermo Fisher Scientific) was
added to 5.6 mL of Opti-MEM. The solutions were incubated sepa-
rately for 10 min at room temperature and then combined. After
gentle mixing the combined solution was incubated for 20 min
and then added directly to the cultured cells. The cells were trans-
fected for 48 h at 37 C before harvesting.
Cells were collected, centrifuged and placed in a siliconized
1.5 mL tube. Cells were lysed by resuspension in Dulbecco’s
phosphate buffered saline with calcium and magnesium (DPBS,
Thermo Fisher Scientific) with 2.5% of 1 M ammonium sulfate,
0.5% Triton X-100 (Thermo Fisher Scientific), 0.1% Benzonase
(Sigma) and 0.1% Plasmid safe (Epicentre). The lysis was then
incubated overnight at 37 C to allow for capsid maturation.
The following day, the solution was adjusted to 0.8 M NaCl
and incubated on ice for 10 min. The salt lysate was double-
clarified by centrifugation at 5000g for five minutes. Capsids
were purified by ultracentrifugation with an Optiprep gradient
[26]. SDS-PAGE gels were run on each gradient fraction to deter-
mine if the fraction contained enough L1 to be visually evident.
Fractions containing L1 were pooled for use in the HPV antibody
immunoassay.2.2. Fabrication of paper-based HPV antibody immunoassay
All materials for the paper-based HPV antibody immunoassay
were cut using a CO2 laser cutter (Universal Laser Systems).
Devices were constructed from 10 mil Dura-lar (Blick Art Supplies,
Galesburg, IL) and 5 mil adhesive-backed Dura-lar (Blick Art Sup-
plies). The lateral flow channel was cut from 2 mil backed high-
flow nitrocellulose (HF090, Millipore). The reagent storage and
release pads were cut glass fiber pads (Grade 8951, Ahlstrom,
Helsinki, Finland). The wicking pad was cut from cellulose (C083,
Millipore). The plasma separation membrane was cut from a com-
mercially available glass fiber filter (LF1, GE Healthcare Life
Sciences).
The paper-based HPV antibody immunoassays were assembled
as shown in Fig. 1. The nitrocellulose strip has three consecutive
test zones to capture anti-HPV 16 antibodies and one positive con-
trol capture location. The test zones were created by twice pipet-
ting 0.4 lL of the HPV16 L1 VLP suspension on each test location,
with drying of the devices at 37 C for ten minutes between pipet-
tings. The first capture location was spotted with HPV16 L1 VLPs
diluted one to four (25 lg/mL for a total of 20 ng VLP) in phosphate
buffered saline (PBS) and the second and third locations were spot-
ted with HPV16 L1 VLPs diluted one to two in PBS (50 lg/mL;
40 ng). The positive control location was spotted once with
0.4 lL of 44 lg/mL human IgG (Thermo Fisher Scientific, Waltham,
MA) diluted in PBS.
The nitrocellulose strips were dried for one hour at 37 C. The
nitrocellulose strips were then blocked by completely submerging
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sucrose (Sigma-Aldrich, St. Louis, MO) and 0.25% w/v
Polyvinylpyrrolidone (40 kD, Sigma-Aldrich, St. Louis, Missouri).
After blocking for 30 min, the strips were dried for 30 min at
37 C. The devices were then completely assembled by placing
the glass fiber pads, nitrocellulose strips, plasma separation mem-
brane and wicking pad as depicted in Fig. 1(A). To create stable
detection antibody, 40 nm diameter gold conjugated goat anti-
Human IgG (50 OD, BioAssay Works, Ijamsville, MD) was diluted
one-to-five in PBS with 1% w/v bovine serum albumin (BSA), 5%
sucrose (Sigma-Aldrich, St. Louis, Missouri) and 5% trehalose
(Sigma-Aldrich, St. Louis, Missouri). Five microliters of the diluted
antibody gold conjugate was spotted on the detection antibody
glass fiber pad. The entire device was then dried overnight at room
temperature. All devices were fabricated one day prior to clinical
testing and stored at room temperature until use.
2.3. Clinical testing
The pilot study was performed at the Baylor College of Medicine
with the approval of the Institutional Review Board of Baylor
College of Medicine. Informed consent was obtained from each
subject. Subjects were students and staff at the Baylor College of
Medicine or Rice University. Subjects were eligible for inclusion if
they were 18 or older and had a history of being sexually active.
Subjects were ineligible if they had a history of diagnosis of any
immunodeficiency disorder, diagnosis of HIV, Hepatitis B or
Hepatitis C or if they were currently using steroids or other
immunosuppressive medications. After consent, subjects were
asked a brief series of questions including the number of HPV vac-
cine dose he/she had received, the type of HPV vaccine and the
number of sexual partners he/she had in the last six months.
The complete supplies required for each test are shown in Fig. 1
(B). All testing was performed by a nurse and trained graduate
research assistant. A finger prick was performed using a high-flow
microtainer lancet (BD Diagnostics, Franklin Lakes, NK). Blood
was collected using a 20 lL microsafe capillary tube (Safe-Tec,
Ivyland, PA) and immediately dispensed onto the plasma separa-
tion membrane. While the plasma separated, PBST was dispensed
onto the glass fiber reagent pads. A 20 lL exact volume transfer pip-
ette was used to place 20 lL of PBST on both the first wash glass
fiber pad and the detection antibody pad. A 40 lL exact volume
transfer pipette was used to dispense PBST on the second wash
pad. Next, the adhesive was exposed by peeling back the paper cov-
ering. Once the plasma reached theminimumplasma line, shown in
Fig. 1(A), the device was folded in half to initiate the test by placing
the glass fiber pads in direct contact with themain lateral flow strip.
If the plasma did not reach the minimum plasma line, the test was
considered invalid. Plasma reached the plasma line after one to two
minutes. Completed tests were scanned at 800 dots per inch (DPI)
using a flatbed color scanner, 35 min after folding the device.
Images were analyzed both subjectively and objectively to
determine if the test result was positive or negative. The images
were randomized and given to three independent reviewers
blinded to the HPV vaccine status of the tested individual. The
reviewers were told to determine whether each test was positive
based on the presence of signal at two or more test zones. Images
were also analyzed quantitatively using a custom MATLAB script;
analysis was performed only on the green channel, where contrast
is greatest for the gold detection system. After selecting the green
channel, the image was inverted so that higher pixel intensities
corresponded to higher signal. A fixed-size region of interest
(ROI) was manually placed at each test zone and at the positive
control site. Three background ROIs, equal in size to the test zone
ROIs, were automatically placed halfway between successive
capture locations. In each row of the ROI, the pixel value corre-sponding to the 95th percentile was calculated. The signal in each
ROI was defined as the average of the 95th percentile value calcu-
lated for each row. The 95th percentile was chosen instead of the
maximum value to mitigate the effect of debris in the test ROI. Sig-
nal from the three background ROIs were averaged together to
define the background signal for each device. The signal-to-
background ratio (SBR) was defined for each test zone location
and positive control location by dividing the signal at each corre-
sponding ROI by the mean background signal. We plotted the
mean SBR for each capture zone location and compared results
for unvaccinated subjects and those who reported receiving one,
two or three doses of the HPV vaccine. Differences in mean
signal-to-background ratios were evaluated using an unpaired
two-tailed Student’s t-test; p-values of less than 0.05 were consid-
ered statistically significant.
2.4. Dried reagent storage
To determine the stability of the dried reagents, a simplified
device with only a single test zone location, shown in Fig. 3(A),
was fabricated. The test zone was created by pipetting 0.4 lL of
50 lg/mL HPV16 L1 VLPs in PBS on the nitrocellulose test location.
The positive control was created by spotting 0.4 lL of 44 lg/mL
anti-human IgG at the control location. The nitrocellulose was then
dried for 10 min at 37 C. Another 0.4 lL of 50 lg/mL HPV16 L1
VLPs was pipetted onto the test zone, and the nitrocellulose was
dried for an additional 60 min at 37 C. The nitrocellulose was
blocked and dried reagent pads were prepared identically to the
paper-based HPV antibody immunoassay used for clinical testing.
After the devices dried overnight, they were placed in a 4.5 mil
thick Mylar foil pouch (Impak, Los Angeles) with two grams of
molecular sieve (Impak, Los Angeles). Three assembled stability
testing devices were placed in each bag. The foil pouches were
sealed using a constant heat bag sealer. Three of the devices were
tested immediately, and the remaining devices were then placed in
a chamber at 37 C with 85% relative humidity. The remaining
devices were tested at 10, 15, 20 and 30 days after being exposed
to high heat and humidity.
Plasma from an individual who had received three Gardasil HPV
vaccine doses was used as the sample for all devices. Collection of
blood was approved by the Rice University Institutional Review
Board. Ten mL of blood was collected into a citrate dextrose solu-
tion A tube from a venous draw by a certified phlebotomist. The
blood was then centrifuged at 1000g for 10 min at 4 C. The super-
natant plasma was collected and centrifuged at 10,000g for 10 min
at 4 C. The plasma was then aliquoted and stored at 20 C until
needed for testing.
To test the devices at each time point, the glass fiber pads were
rehydrated using the exact volume transfer pipettes as described
above. Then, 5 lL of the collected plasma was pipetted onto the
sample glass fiber pad. Once the plasma reached the minimum
plasma line, the sample glass fiber pad was removed, and the
device was folded to initiate flow. This is to prevent the presence
of the glass fiber pad from affecting the flow profile of the stability
testing lateral flow strip. This step is not needed in the paper-based
HPV antibody clinical test because flow from the plasma separation
membrane ceases after red blood cells reach the nitrocellulose.
After 35 min, images were obtained at 800 DPI using a flatbed
scanner. Image analysis was performed similarly to the procedure
used for the standard device. Fixed-size ROIs were manually placed
at the test capture location and positive control location. Back-
ground ROIs of the same size as the test ROIs were automatically
selected midway between the test zone and positive control loca-
tion and midway between the positive control location and wick-
ing pad. Analysis was then performed identically to the standard
device.
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Thirty-five subjects were enrolled in the study to evaluate the
ability of the paper-based HPV antibody immunoassay to deter-
mine HPV vaccination status. After the first five subjects, the device
blocking method was modified to improve device stability at 37 C.
The original blocking solution included 2% BSA that degraded in
the presence of high heat. The blocking procedure was modified
as described in the methods. Results from the first five subjects
are thus not included in the analysis. For the remaining 30 tests,
the plasma failed to reach the minimum plasma line for two sub-
jects. A summary of the data from the remaining 28 patients with
valid results is provided in Table 1. After 35 min, the positive con-
trol signal was visible in all 28 devices, indicating completion of
the assay.Table 1
Summary of subjects in pilot study.
No HPV vaccines One dose
Number of volunteers 10 3
Median age (years) 28 24
(Range) (23–43) (23–25)
Average time since last vaccine (years) – 3.5
(Range) (0.5–8)
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Three-doseA B
One-doseC
1 2 3
D
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Fig. 2. Results of the pilot study. Representative images of the paper-based HPV VLP imm
(B) two doses of HPV vaccines, (C) one dose of HPV vaccine and (D) no HPV vaccine. (E)
vaccines received.Example images of completed paper-based HPV antibody
immunoassays for individuals who reported receiving zero, one,
two and three HPV vaccines are provided in Fig. 2(A–D). All 15 tests
from subjects who reported receiving two or three doses of the
HPV vaccine, were judged positive by all three observers based
on the presence of signal at least two test zones (sensitivity = 100%,
95% CI = 78–100%). Twelve of the thirteen tests from subjects who
reported receiving one or zero doses of the HPV vaccine were
judged negative by all three observers (specificity = 92%, 95%
CI = 64–100%). One test from an unvaccinated subject was judged
negative by one reviewer and positive by two reviewers.
Fig. 2(E) shows a quantitative comparison of the signal-to-
background at each capture location for subjects stratified by the
number of HPV vaccines they reported receiving. The mean SBR
is significantly higher for individuals who reported receiving threeHPV vaccine Two dose HPV vaccines Three dose HPV vaccines
5 10
28.5 25
(22–34) (23–35)
7.9 4.8
(0.75–16) (012)
Test Zones Control Zone
Two-dose
1 2 3
Unvaccinated
Test Zones Control Zone
1 2 3
3
one
unoassay after 35 min for individuals who received (A) three doses of HPV vaccine,
Average signal-to-background ratio at each test zone stratified by number of HPV
B.D. Grant et al. / Vaccine 34 (2016) 5656–5663 5661or two vaccine doses than for unvaccinated individuals and indi-
viduals who reported receiving one vaccine (p < 0.01 for all com-
parisons). There were no statistically significant differences in
the mean SBR at any test zone between subjects who received
two or three HPV vaccines (p = 0.53, 0.40, 0.71 at the first, second
and third test zone, respectively). Similarly, there were no signifi-
cant differences between the mean SBR of tests from unvaccinated
subjects in comparison to subjects who had received a single HPV
vaccine dose (p = 0.22, p = 0.22, p = 0.82, at test zones one, two and
three, respectively). By defining a positive test as any test having a
signal-to-background ratio of at least 1.2 at two or more test zones,
all tests from individuals with two more HPV vaccines were
correctly categorized as positive and all other tests as negative.
This cut-off value was chosen retrospectively to effectively sepa-
rate the two groups.
The quality of the L1VLPs and appropriateness of this cut-off
value were evaluated by performing the assay with a mouse mon-
oclonal HPV16 L1 antibody (Abcam ab69, Cambridge, UK) spiked
into plasma from an unvaccinated individual. To detect this mouse
antibody, 40 nm diameter gold conjugated goat anti-mouse IgG
(50 OD, BioAssay Works, Ijamsville, MD) was used. Twofold serial
dilutions from 32 lg/mL to 0.5 lg/mL were tested in triplicate.
The results of this testing revealed that 2 lg/mL is the lowest con-
centration that would classify as positive based on a threshold of a
signal-to-background ratio of at least 1.2 at two or more test zone
locations. Results of the assay show signal-to-background ratios
that are antibody dose dependent, suggesting the presence of
necessary conformational epitopes on the VLPs. Using the cLIA,
Villa et al. [24] showed that those with natural infection hadDetecon 
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Fig. 3. Stability testing of paper-based HPV VLP immunoassays. Devices were stored at
positive control zone. The same sample, plasma from an individual who had received 3 H
The mean signal-to-background ratio decreased 10% over the course of 30 days at the teanti-HPV16 levels of 50–100 milli-Merck Units per milliliter
(mMU/mL), and those with a history of HPV vaccination showed
levels of greater than 800 mMU/mL. According to Opalka et al.,
50 ng/mL is approximately equal to 4.6 mMU/mL [30]. Using this
conversion, individuals with a previous HPV infection have anti-
body levels between 500 and 1000 ng/mL while those with full
vaccination history have levels above 8 lg/mL. Therefore, the test’s
cutoff of 2 lg/mL is appropriate to separate these two groups. This
spiking experiment was performed using a mouse antibody and
some differences may exist with human antibodies, which is why
the clinical pilot study was necessary to establish an appropriate
SBR cut-off.
The results of stability testing are shown in Fig. 3(B). After
10 days of storage, the mean SBR decreased by 7% at the test zone
and by 17% at the positive control zone. From day 10 to day 30, sig-
nal decreased by an additional 3.3% at the test zone and an addi-
tional 6.8% at the control zone. Because SBR both increased and
decreased at measurements taken between these two time points,
up-and-down fluctuations in the SBR between these two time
points are likely due in part to device-to-device variability. The
Eppendorf Research Plus pipette used for spotting the capture anti-
bodies on the nitrocellulose strips has a random error of ±6% at the
volume being dispensed. Automated liquid dispensers would
reduce the variability (noise) between devices. However, despite
this variably the test could still discriminate unvaccinated individ-
uals and individuals who reported having a single vaccine from
those who reported receiving two or more HPV vaccine doses.
The decrease in SBR over time is likely due to reduction in activity
of the VLPs and gold conjugates as a result of degradation in highTest Zone
Posive ControlPlasma Sample
Test
Posive Control
20 30
elave Humidity
37 C and 85% relative humidity for 30 days. Each device contained a test zone and
PV vaccines, was used to evaluate the performance of the devices at all time points.
st zone and 23% at the positive control zone.
5662 B.D. Grant et al. / Vaccine 34 (2016) 5656–5663heat conditions. By artificially reducing the SBR determined for all
test zone locations for the pilot study devices, we can examine the
effect this decreased SBR would have on quantitative assay perfor-
mance. Using the same 1.2 cutoff point and reducing all test zone
SBRs by 10.3%, we would correctly identify all of those who
reported receiving one or fewer vaccines. It would correctly iden-
tify 14 of 15 of those who reported receiving two or more HPV
vaccines.
The initial results of this test are promising; however, a large-
scale study is necessary to understand the repeatability and
robustness of the paper-based HPV VLP immunoassay. There were
only three individuals who reported receiving one HPV vaccine and
five who reported receiving two HPV vaccines. Therefore, a larger
study is necessary to quantify the accuracy of this test. A false-
positive was recorded by two reviewers. It is possible the faint
signal seen in this device was due to a previous natural HPV16
infection. We chose to include only subjects with a history of
sexual activity to increase the likelihood of participants having a
history of natural HPV infection; however, we do not know the
natural history of infection for any participants. To reduce the like-
lihood of false positives, future iterations of the immunoassay
could use HPV16 L1 VLPs at one test zone and HPV18 L1 VLPs at
a second test zone. We hypothesize this will increase specificity
because all vaccinated individuals will have antibodies to both
HPV16 and HPV18; however, very few individuals will have anti-
bodies to both types as a result of natural infection.
In future testing, device imaging or visual interpretation should
occur as soon as the positive control signal is visible instead of a
fixed duration of 35 min. This will allow for faster time to results
in most cases. Additionally, when plasma does not reach the min-
imum plasma separation line, this indicates an insufficient volume
of blood and the test should be repeated with a new device and a
new finger prick. The appropriateness of this assay design also
depends on ongoing research evaluating long-term efficacy one,
two or three dose HPV vaccination regimens. The World Health
Organization (WHO) recommends two doses spaced at least
6 months apart for those who receive their first vaccine before
the age of 15 [31]. While guidelines may continue to change, vary-
ing VLP capture concentrations provides the ability to tune the
assay appropriately. Based on the current WHO recommendations,
if the paper based immunoassay returns a negative result, the
patient should receive one HPV vaccine. A follow-up appointment
should be scheduled for six months later, where the immunoassay
should be repeated to see if the patient has now received a total of
two HPV vaccines. If the test is negative again, the patient should
receive an additional vaccine.
A primary limitation of this study was reliance of self-reporting
of HPV vaccine status. There are several factors which lead us to
believe that the accuracy of this self-reporting is higher than that
in the study reported by Stupiansky et al. [20]. The subjects in
the Stupiansky et al. study were ages 14–17. In this study, all par-
ticipants were pursuing or had completed post-graduate education
in biomedical sciences and actively volunteered to participate in an
HPV-vaccine related study. Two subjects reported they were
unsure if they had received two or three HPV vaccines. They called
their primary care physician and verified the number of HPV vac-
cines they had received before participating. All other subjects
reported being confident in their HPV vaccination history. In future
validation studies, medical records should be obtained to ensure
accuracy of the participants HPV vaccination history.
The utility of this device extends beyond individual HPV vacci-
nation status screening. With small modifications, the device could
be utilized for other serological assays by substituting the appro-
priate antigen for the HPV VLPs. Additionally, instead of being used
for individual screening, it could be used in population surveillance
to estimate vaccination rates in a given region. The cost-of-goodsfor small-scale production of the current device prototype is
$1.38, including the lancet and exact volume transfer pipettes. In
order to make the device more amenable to mass manufacturing,
the device should be housed in a more traditional lateral flow assay
injection-molded cassette. Future improvements could include
volume-metering components in the cassette, eliminating the need
for exact volume pipettes. Finally, adding an HPV18 capture loca-
tion could improve the specificity of the test.Conflicts of interest
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